GlobeNewswire·Nov 4, 2026, 9:05 AM ET

Hemab Therapeutics to Present Clinical and Preclinical Data from Multiple Blood Coagulation Programs at the 68th ASH Annual Meeting and Exposition

COAG

Hemab Therapeutics announced first clinical data for sutacimig in Factor VII deficiency (FVIID) showing multi-fold accumulation of endogenous FVII(a) & shortened prothrombin time after a single subcutaneous dose in Phase 2b participants.
Preclinical data for HMB-003 demonstrated reduced severe menstrual bleeding days & week-long antifibrinolytic activity in a cynomolgus monkey model.
Two participants with severe congenital FVIID received sutacimig in the Phase 2b study; both experienced baseline prothrombin times ≥180 seconds that shortened by >50% post-dosing with low-grade adverse events.
Sutacimig produced ~5x sustained accumulation of endogenous total FVII(a) maintained through Day 22, supporting potential infrequent dosing regimens.
HMB-003 acts as a selective plasmin inhibitor with a 6–7 day half-life in minipigs, providing complete ex vivo fibrinolysis inhibition for up to 7 days before returning to baseline.
The Phase 1 clinical trial for HMB-003 (NCT07798505) in healthy volunteers is ongoing with initial data expected in mid-2027.
First pharmacokinetic & pharmacodynamic results for sutacimig & preclinical data for HMB-003 will be presented at the 68th ASH Annual Meeting in New Orleans from December 12–15, 2026.
Sutacimig holds Fast Track, Orphan Drug, & Breakthrough Therapy designations from the FDA for Glanzmann thrombasthenia, with additional regulatory designations in the UK & EU.
HMB-003 is engineered as a non-hormonal, long-acting antifibrinolytic therapy targeting heavy menstrual bleeding to address limitations of current short-half-life treatments like tranexamic acid.